REDISOL Drug Patent Profile
✉ Email this page to a colleague
When do Redisol patents expire, and when can generic versions of Redisol launch?
Redisol is a drug marketed by Merck and is included in one NDA.
The generic ingredient in REDISOL is cyanocobalamin. There are nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the cyanocobalamin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Redisol
A generic version of REDISOL was approved as cyanocobalamin by PADAGIS ISRAEL on September 9th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for REDISOL?
- What are the global sales for REDISOL?
- What is Average Wholesale Price for REDISOL?
Summary for REDISOL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 2 |
| Patent Applications: | 57 |
| DailyMed Link: | REDISOL at DailyMed |
US Patents and Regulatory Information for REDISOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | REDISOL | cyanocobalamin | INJECTABLE;INJECTION | 006668-010 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
